{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:40:57Z","timestamp":1790401257401,"version":"4.1.0"},"reference-count":87,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic hepatitis C virus (HCV) management has historically been challenging, particularly in Egypt, the country with the highest global disease prevalence. The introduction of direct\u2010acting antivirals (DAAs) has revolutionised treatment, providing high rates of sustained virologic response (SVR) with fewer adverse events compared to previous therapies. In Egypt, the locally produced generics of sofosbuvir\/daclatasvir (SOF\/DAC) have been integral to the national HCV elimination programme, treating millions effectively and affordably, demonstrating similar efficacy and safety to brand\u2010name drugs. Although not currently present in most international guidelines, this cost\u2010effective regimen offers a viable option for large\u2010scale elimination programmes similar to Egypt's successful experience. This review synthesises real\u2010world Egyptian data and highlights the efficacy and safety of the SOF\/DAC combination in various population groups. High sustained virological response (SVR) rates were observed across diverse patient populations, including those with advanced liver disease. However, limitations regarding long\u2010term follow\u2010up, especially HCC surveillance, were identified, underscoring the need for further research. Additionally, the review underscores the success of local Egyptian pharmaceutical policies in reducing treatment costs and securing access for all infected individuals. The Egyptian experience offers valuable insights into the potential for replicating its success, particularly in other high\u2010burden regions.<\/jats:p>","DOI":"10.1111\/jvh.70032","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:30:44Z","timestamp":1748417444000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Leading Role of Sofosbuvir\/Daclatasvir in Achieving Hepatitis C Elimination in Egypt"],"prefix":"10.1111","volume":"32","author":[{"given":"Tamer","family":"Elbaz","sequence":"first","affiliation":[{"name":"Endemic Hepatology and Gastroenterology Department, Faculty of Medicine Cairo University  Cairo Egypt"},{"name":"Hepatology and Gastroenterology Department, Faculty of Medicine New Giza University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al\u2010Naamani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology The Medical City for Military and Security Services  Muscat Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Abosheaishaa","sequence":"additional","affiliation":[{"name":"Internal Medicine Icahn School of Medicine at Mount Sinai, New York City Health and Hospitals, Queens Hospital Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alswat","sequence":"additional","affiliation":[{"name":"Liver Disease Research Center, College of Medicine King Saud University  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El\u2010Kassas","sequence":"additional","affiliation":[{"name":"Endemic Medicine Department, Faculty of Medicine Helwan University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01320-X"},{"issue":"8","key":"e_1_2_9_3_1","article-title":"Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions","volume":"15","author":"Bernal L. A.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_9_4_1","unstructured":"World Health Organization (WHO) \u201cGlobal Progress Report on HIV Viral Hepatitis and Sexually Transmitted Infections \u201d2021 accessed August 9 2023 https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27165"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12397"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i4.1421"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12668"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S113681"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1758065"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i10.841"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13923"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13266"},{"key":"e_1_2_9_14_1","unstructured":"World Health Organization \u201cCombating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief \u201d2016 https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/206453\/WHO_HIV_2016.04_eng.pdf\/jsessionid=CADC5914BBC22D9F5FEBA9B2033892A3?sequence=1."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00389-6"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2145883"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1240781"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13264"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2014.11.004"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203110110"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24609"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14428"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13769"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14271"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2017.03.012"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1912628"},{"key":"e_1_2_9_29_1","volume-title":"Egypt Health Issues Survey","author":"Ministry of Health, Egypt, El\u2010Zanaty and Associates, Egypt, ICF International","year":"2015"},{"key":"e_1_2_9_30_1","unstructured":"F.El\u2010Zenati \u201cWay A Knowledge and Prevalence of Hepatitis C. Egypt Demographic and Health Survey \u201d2008 accessed July 30 2024 https:\/\/dhsprogram.com\/pubs\/pdf\/FR220\/FR220.pdf."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15843"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13311"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13148"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9616234"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9868-8"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14482"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S160593"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871526518666180716141806"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9861-2"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1629287"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886317666220510184749"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14022"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886314666191001151314"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-03120-9"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2021.06.001"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.07.025"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30257-0"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001228"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14538"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001695"},{"key":"e_1_2_9_51_1","unstructured":"\u201cDaklinza AK (daclatasvir): Highlights of Prescribing Information \u201daccessed July 25 2024 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206843Orig1s000lbl.pdf."},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S62014"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S275721"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-020-00070-4"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.5334\/gh.906"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.EGY-S4-28"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14913"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15672"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-023-00537-x"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25362"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25210"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003282"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001838"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13032"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001968"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i16.2247"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2017.07.014"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25287"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-019-00167-3"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2004117"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trz079"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002287"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001250"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1171"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02598.x"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-023-00197-1"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001903"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399815666190531091128"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2023.12.006"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1951230"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S241948"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001152"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001370"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S167093"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000963"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.06.006"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trz120"},{"issue":"7","key":"e_1_2_9_88_1","first-page":"693","article-title":"DAAs Therapy Associated With Improved Hepatic Fibrosis in HCV\u2010GT4 Patients Co\u2010Infected With HIV. Expert Rev","volume":"13","author":"El\u2010Garem H.","year":"2019","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.70032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T05:01:35Z","timestamp":1764392495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.70032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":87,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/jvh.70032"],"URL":"https:\/\/doi.org\/10.1111\/jvh.70032","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"2024-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70032"}}